News Release, KYORIN Pharmaceutical Co.,Ltd.

RELEASE OF "MUCODYNE® DS50%"

Tue, 08 Jun 2010 18:53:23 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announces the release of Mucodyne® DS50% (Nonproprietary name: L-Carbocisteine), a mucoregulating drug (for adults and children) today.

MARKETING APPROVAL FOR "MUCODYNE® DS50%"

Mon, 18 Jan 2010 17:12:02 +0900

KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Keiji Hirai), a subsidiary of KYORIN Co., Ltd. announced today that the Ministry of Health, Labour and Welfare approved "MUCODYNE® DS50%" (INN: L-Carbocisteine), Mucoregulating drug, on January 15, 2010.

Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Thu, 07 Jan 2010 15:59:18 +0900

Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Tokyo, Japan, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of Kyorin Co., Ltd., and Ono Pharmaceutical Co., Ltd. ("Ono") (Osaka, Japan, President: Gyo Sagara) jointly announced that each company filed a new drug application for orally disintegrating tablet of imidafenacin (INN), a drug for the treatment of overactive bladder on December 24, 2009. It was originally launched in June 2007 as Uritos Tablets 0.1mg (by Kyorin) or Staybla Tablets 0.1mg (by Ono) in a form of conventional film coating tablets.

Execution of License Agreement on Neramexane for Tinnitus with Merz Pharmaceuticals for Japan Territory

Thu, 05 Nov 2009 09:47:17 +0900

KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Chiyoda-ku, Tokyo, President: Keiji Hirai, Ph.D.), a wholly owned subsidiary of KYORIN Co., Ltd., today entered into a License Agreement for Neramexane, a tinnitus treatment product currently being developed in the US and Europe, with Merz Pharmaceuticals GmbH ("Merz") (Head office: Frankfurt am Main, Germany, CEO: Martin Zügel, Ph.D.) for the territory of Japan.

KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries

Tue, 29 Sep 2009 14:15:40 +0900

Grant of Marketing Right to Senju Pharmaceutical on Gatifloxacin Ophthalmic Solution in China

Mon, 27 Jul 2009 15:33:43 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Tokyo, President: Keiji Hirai, Ph.D.) today signed a License Agreement with Senju Pharmaceutical Co., Ltd. ("Senju") (Head office: Osaka, President: Yukoh Yoshida), concerning the grant of an exclusive marketing right to Senju on Gatifloxacin ophthalmic solution for China. Gatifloxacin is a broad spectrum synthetic antibacterial agent originated by Kyorin.

Change of Representative Director and President at KYORIN Pharmaceutical

Fri, 03 Apr 2009 19:28:36 +0900

KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Co., Ltd., announces that a meeting of its Board of Directors held on April 3, 2009 informally resolved to make the change of KYORIN Pharmaceutical's Representative Director and President.
The change will be made pending a resolution of the ordinary general shareholders meeting of KYORIN Pharmaceutical scheduled in June 2009 and a subsequent meeting of the Board of Directors of KYORIN Pharmaceutical.

Execution of Licensing and Supply Agreement on Uritos® Tablets with SPIMACO

Fri, 27 Feb 2009 15:21:15 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Itaru Kojo) has entered into a License and Supply Agreement with Saudi Pharmaceutical Industries & Medical Appliances Corporation ("SPIMACO") (Head office: Riyadh, Saudi Arabia, President: Dr. Abdullah Bin Abdulaziz Al Abdulkader), under which KYORIN Pharmaceutical granted to SPIMACO an exclusive right to develop, register, import, and market Uritos® Tablets (generic name: Imidafenacin), a therapeutic agent for overactive bladder (OAB) in thirteen countries in the Middle East and North Africa (MENA) region, including Saudi Arabia.

Paper on Clinical Trial of MUCODYNE® for COPD Patients (PEACE Study) Chosen for THE LANCET Paper of the Year 2008

Thu, 29 Jan 2009 08:19:40 +0900

Tokyo-January 29, 2009, KYORIN Co., Ltd. announces that a research paper※１on a clinical trial (PEACE Study※２) of MUCODYNE®, sold by its wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Itaru Kojo), has been selected Paper of the Year by THE LANCET.

Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase

Wed, 24 Dec 2008 19:18:57 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) obtained approval for an additional regimen and dose (4,000 mg divided into two doses per day) of Pentasa® Tablets 250 and Pentasa® Tablets 500 (generic name: mesalazine) for the treatment of ulcerative colitis in its active phase. These products are intended for the treatment of ulcerative colitis and Crohn's disease.

Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalazine drugs like Pentasa and steroids.

Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500

Wed, 01 Oct 2008 22:08:57 +0900

KYORIN Co., Ltd. Announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) launched today Pentasa® Tablets 500 as an additional formulation to the Pentasa®250 (generic name :mesalazine) already on the market.

Since July 1996, KYORIN Pharmaceutical Co., Ltd. and Nisshin Kyorin Pharmaceutical Co., Ltd. both have marketed Pentasa® Tablets 250 and have contributed to the treatment of ulcerative colitis and Crohn's disease.

Pentasa® Tablets 500 lessen the burden on patients by reducing the number of tablets currently marketed Pentasa® Tablets 250 that are administered per day. Pentasa® Tablets 500 were developed for the purpose of improving adherence as well as QOL.

To distinguish them from the round Pentasa® Tablets 250, Pentasa® Tablets 500 came in a capsule form.

On October 1, 2008, KYORIN Pharmaceutical Co., Ltd. merged Nisshin Kyorin Pharmaceutical Co., Ltd. into KYORIN Pharmaceutical Co., Ltd. we will exclusively market Pentasa® Tablets 250, Pentasa® Enema 1g and Pentasa® Tablets 500 and will make an ongoing contribution to the treatment of inflammatory bowel diseases by providing the latest information, including peripheral information.

Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan

Tue, 30 Sep 2008 22:10:06 +0900

Kyorin Pharmaceutical Co., Ltd. (Tokyo, President: Itaru Kojo), a wholly owned　subsidiary of Kyorin Co., Ltd., and Dainippon Sumitomo Pharma Co., Ltd. (Osaka, President: Masayo Tada) announce that they have decided to voluntarily discontinue commercialization of Gatiflo® (gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan as of September 30, 2008.

Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent

Wed, 20 Aug 2008 22:12:20 +0900

Kyorin Pharmaceutical Co., Ltd (Tokyo, President: Mr. Itaru Kojo), a subsidiary of Kyorin Co., Ltd. announced that the target goals of major endpoints of overseas Ph1b (in US) and Ph2a (in US and India) clinical studies for KRP-104 were achieved. KRP-104 is a DPP-4 inhibitor originated by Kyorin Pharmaceutical and jointly filed IND to US FDA by Kyorin and ActivX Bioscience, Inc. (California, USA, Chairman, President: Dr. John W. Kozarich), a wholly owned subsidiary of Kyorin Pharmaceutical.

Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan

Tue, 22 Apr 2008 22:13:39 +0900

Execution of License Agreement on Flutiform™ , an Anti-asthmatic Treatment, in Japan Kyorin Pharmaceutical Co., Ltd. (Tokyo, President: Ikuo Ogihara), a subsidiary of Kyorin Co., Ltd., announces that it has entered into a License Agreement with SkyePharma PLC (United Kingdom, CEO: Mr. Frank Condella) as of April 22, 2008 on Flutiform™ , an anti-asthmatic treatment currently under development for Europe and the USA.

Launch of KIPRES Tablets 5mg

Fri, 18 Apr 2008 22:16:04 +0900

KYORIN Co., Ltd. announces that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) launched today "Kipres® Tablets 5mg" (INN: montelukast sodium), a leukotriene receptor antagonist / bronchial asthma and allergic rhinitis treatment drug, which was already approved on January 25, 2008.

Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products containing montelukast sodium, "Kipres® Tablets 10mg" for adults and "Kipres® Chewable Tablets 5mg" for pediatric patients aged 6 years and older, since August 2001, and "Kipres® Oral Granules 4mg" for pediatric patients aged 1 year and older but under 6 years since October 2007. In addition, the company has obtained a marketing approval of allergic rhinitis in adults for "Kipres® Tablets 10mg" in January 2008.

Treatment by the daily single dose (bed time) of "Kipres® Tablets 5mg" has demonstrated its efficacy and safety profiles comparable to those of "Kipres® Tablets 10mg" in adult allergic rhinitis and improved three major symptoms of allergic rhinitis; stuffy nose, runny nose and sneezing. This product has approval for the treatment of bronchial asthma in adults while approved dose (dosage for bronchial asthma in adults is 10mg).

KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT) and urology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis treatments through aiming to immediately penetrate Kipres into the markets of respiratory and ENT.